^
    14h
    Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Vejle Hospital | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    15h
    Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=28, Completed, NovoCure Ltd. | Unknown status --> Completed | Trial completion date: Sep 2021 --> Jun 2024 | Trial primary completion date: Sep 2021 --> Jun 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Herceptin (trastuzumab) • capecitabine • oxaliplatin
    1d
    Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (clinicaltrials.gov)
    P3, N=340, Active, not recruiting, Merck Sharp & Dohme LLC | N=800 --> 340 | Trial completion date: Jul 2028 --> Mar 2025 | Trial primary completion date: Jul 2028 --> Mar 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin
    2d
    Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer (clinicaltrials.gov)
    P4, N=20, Recruiting, yangjianjun | Initiation date: Jan 2024 --> Sep 2024
    Trial initiation date
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine • oxaliplatin
    3d
    The Sagittarius Trial (clinicaltrials.gov)
    P3, N=700, Recruiting, IFOM ETS - The AIRC Institute of Molecular Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Signatera™
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • 5-fluorouracil • Vectibix (panitumumab) • Perjeta (pertuzumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    3d
    Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk (clinicaltrials.gov)
    P4, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P4 trial
    |
    capecitabine • Zepsun (donafenib)
    4d
    Randomized, cohort clinical study of sequential use of adebelimab and CAPOX regimen in long-term or short-term radiotherapy for locally advanced rectal cancer (ChiCTR2400089934)
    P=N/A, N=60, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial • Metastases
    |
    capecitabine
    4d
    Locally advanced head and neck squamous carcinoma after radical treatment for high-risk patients, ripley's single joint capecitabine maintenance treatment of phase II clinical study (ChiCTR2400090080)
    P2, N=60, Recruiting, Tumor Hospital Affiliated to Guizhou Medical University; Tumor Hospital Affiliated to Guizhou Medical University
    New P2 trial • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    capecitabine
    4d
    Dalcilib combined with aromatase inhibitors and capecitabine neoadjuvant therapy Open, single arm, multi arm treatment of HR positive/HER2 negative early breast cancer Central research (ChiCTR2400090076)
    P2, N=30, Not yet recruiting, Fujian Medical University Affiliated Union Hospital; Fujian Medical University Affiliated Union Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 expression • PGR expression
    |
    capecitabine
    4d
    A Prospective, Multicenter Clinical Study of the Efficacy and Safety of First-Line Treatment with Ivonescimab in Combination with XELOX for Unresectable Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (ChiCTR2400089954)
    P2, N=30, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • Yidafan (ivonescimab)
    4d
    A single-arm, single-center clinical study of chidamide in combination with vinorelbine and capecitabine in the treatment of HER2-negative advanced breast cancer (ChiCTR2400090102)
    P2, N=26, Not yet recruiting, ChongQing university cancer hospital; ChongQing university cancer hospital
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • vinorelbine tartrate • Epidaza (chidamide)
    4d
    The role of low-dose radiotherapy in maintenance therapy after first-line treatment of HER2-negative advanced gastric cancer (ChiCTR2400089076)
    P2, N=80, Not yet recruiting, Sichuan Mianyang 404 Hospital; Sichuan Mianyang 404 Hospital
    New P2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    |
    capecitabine • oxaliplatin
    4d
    A prospective, single-arm, single-center clinical study of short-course radiotherapy followed by tislelizumab combined with capecitabine as neoadjuvant therapy for locally advanced rectal cancer (ChiCTR2400088935)
    P2, N=33, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New P2 trial • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine
    4d
    A Study of Liposomal Irinotecan (Nal-IRI) with 5 Fluorouracil, leucovorin, and Oxaliplatin (NALIRIFOX) in patients with locally advanced Pancreatic Cancer (ChiCTR2400089619)
    P2, N=20, Recruiting, Jiangsu Province Hospital; Jiangsu Province Hospital
    New P2 trial • Metastases
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur) • Onivyde (nanoliposomal irinotecan)
    4d
    Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer (ChiCTR2400089659)
    P1, N=30, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P1 trial • Combination therapy • Metastases
    |
    MSI (Microsatellite instability) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1
    |
    capecitabine
    7d
    Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, First Affiliated Hospital of Guangxi Medical University
    New P2 trial
    |
    Tyvyt (sintilimab) • capecitabine
    7d
    A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer (clinicaltrials.gov)
    P3, N=885, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • oxaliplatin
    7d
    IMpassion132: A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=595, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • gemcitabine • capecitabine
    7d
    KEYNOTE 811: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (clinicaltrials.gov)
    P3, N=738, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2024 --> Sep 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    8d
    SMALLER: Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer (clinicaltrials.gov)
    P3, N=180, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine
    8d
    CHENDO: CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO (clinicaltrials.gov)
    P2, N=52, Completed, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Unknown status --> Completed | N=150 --> 52
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    capecitabine • fulvestrant
    9d
    Tyme-88-Panct: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=130, Terminated, Tyme, Inc | Completed --> Terminated; Sponsor's decision
    Trial termination • Metastases
    |
    gemcitabine • 5-fluorouracil • capecitabine • sirolimus • racemetyrosine (SM-88)
    10d
    DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (clinicaltrials.gov)
    P3, N=608, Active, not recruiting, Daiichi Sankyo | Trial completion date: May 2025 --> Jul 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    lapatinib • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
    10d
    Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgeon-led Local Treatment in Patients with Limited-metastatic Gastric Cancer (ROSETTE) (clinicaltrials.gov)
    P2, N=82, Not yet recruiting, Shanghai Zhongshan Hospital | Trial completion date: Jul 2028 --> Dec 2028 | Initiation date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2027 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    11d
    HELEN-008: Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer (clinicaltrials.gov)
    P3, N=1979, Recruiting, Henan Cancer Hospital | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive • HER-2 negative + PGR positive
    |
    capecitabine
    14d
    Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=242, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • capecitabine • albumin-bound paclitaxel
    14d
    A phase 1a/b dose-escalation and dose-expansion study to evaluate nLutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in npatients with metastatic castration-resistant prostate cancer (mCRPC) (ACTRN12623001072606)
    P1, N=45, Recruiting, South Metropolitan Health Service (SMHS) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    capecitabine
    14d
    Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management (clinicaltrials.gov)
    P1, N=15, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jul 2025 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine
    14d
    Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice. (PubMed, J Clin Oncol)
    Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase) • NUDT15 (Nudix Hydrolase 15)
    |
    UGT1A1*1*1
    |
    5-fluorouracil • capecitabine • irinotecan • mercaptopurine • thioguanine
    14d
    CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, West China Hospital
    New P2 trial • Metastases
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin • Byvasda (bevacizumab biosimilar)
    15d
    Antimetastatic effect of nanodiamond-conjugated quercetin against colon cancer: an in vivo study. (PubMed, Turk J Biol)
    This study is experimental-based and was designed using a six-group treatment method, namely normal control (KN: not treated by MNU, nanodiamond (ND), or Q); negative control (K-: treated by MNU); positive control (K+: treated by MNU and capecitabine); ND (treated by MNU and NDs); Q (treated by MNU and Q); and NDQ (treated by MNU and NDQ)...The lung tumor metastases in the NDQ group were fewer than in the K- group. NDQ increased Q's anticancer activity, suggesting that NDs have an effective drug delivery property.
    Preclinical • Journal • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9)
    |
    capecitabine
    15d
    Banxia xiexin decoction prevents the development of gastric cancer. (PubMed, World J Clin Oncol)
    BXD has the effect of inhibiting tumor growth rate and delaying the development of GC. Its mechanism of action may be related to the regulation of PI3K-Akt signaling pathway.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6)
    |
    EGFR expression • BCL2 expression • IL6 expression
    |
    capecitabine • LY294002
    16d
    CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Fudan University
    New P2 trial • Metastases
    |
    5-fluorouracil • Tyvyt (sintilimab) • capecitabine • oxaliplatin • irinotecan • Tomudex (raltitrexed)
    16d
    TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=84, Active, not recruiting, Sun Yat-sen University
    New P3 trial • Metastases
    |
    cisplatin • capecitabine • albumin-bound paclitaxel • Kaitanni (cadonilimab)
    16d
    LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov)
    P3, N=545, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    lapatinib • capecitabine • oxaliplatin
    18d
    JANUS: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (clinicaltrials.gov)
    P2, N=312, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date • Metastases
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    19d
    Global Leadership Initiative on Malnutrition Criteria and Immunonutritional Status Predict Chemoadherence and Survival in Stage II/III Gastric Cancer Treated with XELOX Chemotherapy. (PubMed, Nutrients)
    This study highlights the critical role of immunonutritional status, particularly as measured using the GLIM criteria, in maintaining adherence to chemotherapy and improving survival outcomes in patients with gastric cancer. Routine preoperative nutritional assessments using GLIM can help identify high-risk patients, and early nutritional interventions may improve chemotherapy adherence and outcomes. These findings support the integration of nutritional strategies, specifically targeting those identified by the GLIM, into standard care to enhance the efficacy and survival of chemotherapy.
    Retrospective data • Journal • Adherence
    |
    CRP (C-reactive protein)
    |
    capecitabine • oxaliplatin
    22d
    Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) (clinicaltrials.gov)
    P2, N=190, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    paclitaxel • docetaxel • capecitabine • Kisqali (ribociclib) • goserelin acetate
    22d
    HERIZON: A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients with HER2 Positive Advanced Gastric Cancer (clinicaltrials.gov)
    P1/2, N=36, Completed, Imugene Limited | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
    Trial completion • Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    HER-2 overexpression
    |
    cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Her-VAXX
    23d
    RAPIDO vs LCRT vs Upfront Surgery - a Prospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Sengkang General Hospital | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date • Surgery
    |
    capecitabine • oxaliplatin
    23d
    Ischemic cardiopathy induced by capecitabine in gastric cancer: The role of dihydropyrimidine dehydrogenase metabolites. (PubMed, Therapie)
    This work supports the role of toxic 5-FU metabolites generated by dihydropyrimidine dehydrogenase in the occurrence of ischemic cardiopathy among patients with gastric cancer using capecitabine.
    Journal
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    5-fluorouracil • capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    24d
    CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients With Inoperable Localized CRC (clinicaltrials.gov)
    P2, N=124, Not yet recruiting, Fudan University
    New P2 trial
    |
    5-fluorouracil • Tyvyt (sintilimab) • capecitabine • oxaliplatin • irinotecan • Tomudex (raltitrexed)